Vaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Arizona State Retirement System

Arizona State Retirement System raised its holdings in Vaxcyte, Inc. (NASDAQ:PCVX – Get Rating) by 54.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 14,679 shares of the company’s stock after purchasing an additional 5,171 shares during the period. Arizona State Retirement System’s holdings in Vaxcyte were worth $704,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC raised its position in shares of Vaxcyte by 275.5% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 4,359 shares of the company’s stock valued at $104,000 after purchasing an additional 3,198 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Vaxcyte in the 3rd quarter valued at approximately $10,147,000. Ghost Tree Capital LLC raised its position in shares of Vaxcyte by 10.8% in the 3rd quarter. Ghost Tree Capital LLC now owns 360,000 shares of the company’s stock valued at $8,640,000 after purchasing an additional 35,000 shares in the last quarter. Endurant Capital Management LP bought a new stake in shares of Vaxcyte in the 3rd quarter valued at approximately $1,255,000. Finally, Renaissance Capital LLC bought a new stake in shares of Vaxcyte in the 4th quarter valued at approximately $1,258,000. 71.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Needham & Company LLC reiterated a “buy” rating and issued a $58.00 price target on shares of Vaxcyte in a report on Tuesday, February 28th. TD Cowen assumed coverage on Vaxcyte in a report on Tuesday, April 18th. They issued an “outperform” rating for the company. 888 reiterated a “reiterates” rating on shares of Vaxcyte in a report on Tuesday, May 9th. Bank of America boosted their price target on Vaxcyte from $63.00 to $68.00 in a report on Monday, April 17th. Finally, Guggenheim lowered their price target on Vaxcyte from $66.00 to $65.00 and set a “buy” rating for the company in a report on Tuesday, February 28th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $65.00.

Vaxcyte Price Performance

Shares of PCVX opened at $48.25 on Wednesday. The company has a market cap of $4.52 billion, a P/E ratio of -13.95 and a beta of 0.97. The stock has a fifty day moving average price of $41.70 and a 200 day moving average price of $43.52. Vaxcyte, Inc. has a 12 month low of $17.44 and a 12 month high of $54.84.

Vaxcyte (NASDAQ:PCVX – Get Rating) last issued its quarterly earnings data on Monday, February 27th. The company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.11. As a group, research analysts anticipate that Vaxcyte, Inc. will post -2.98 earnings per share for the current year.

About Vaxcyte

(Get Rating)

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia.